Skip to main content

Editor's comment: Knowledge swap shop

Lynn Rouse

The first of many: that appears to be the over-riding theme of this week’s insurance market developments. First we had the groundbreaking strategic partnership struck between Catlin and China Re, in a move both parties expect will prove extremely advantageous in the months and years to come.

The deal may mark the first time a Chinese company has directly invested in Lloyd’s, but both firms believe the rewards will be much greater than a mere entry into the history books.

China Re gains

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@postonline.co.uk or view our subscription options here: https://subscriptions.postonline.co.uk/subscribe

You are currently unable to copy this content. Please contact info@postonline.co.uk to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Insurance Post? View our subscription options

Lloyd’s probe deepens after Clement promotion cleared

Lloyd’s is believed to have widened a fresh investigation into top-level behaviour, just as a report emerged that October’s review of the London Market’s former CEO John Neal’s relationship with his former head of corporate affairs Rebekah Clement ruled it wasn’t inappropriate.

Hidden risks in insurers’ culture and misconduct data

Insurers are under growing regulatory pressure to treat non-financial misconduct as a core conduct risk, according to Loka Venkatramana from Pathlight Associates, who says they should use cultural and behavioural data with the same rigour as financial metrics to identify and address problems before they damage customers, staff or the market.

Most read articles loading...

You need to sign in to use this feature. If you don’t have an Insurance Post account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here